BRCA1 and neoplasm: BRCA1/2 functional loss leads to impaired HRR pathways [40], thereby preventing cells from effectively repairing platinum‐induced DNA damage, resulting in cell cycle arrest, and ultimately enhancing tumor cell sensitivity to platinum‐based chemotherapy.